Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.30 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29231181 | 1.00 | MGAM (0.34) | MGAMGAASIMGAM2GPR3 | |
| SCHEMBL31369258 | 1.00 | MGAM (0.34) | MGAMGAASIMGAM2GPR3 | |
| SCHEMBL29231184 | 1.00 | MGAM (0.34) | MGAMGAASIMGAM2GPR3 | |
| SCHEMBL29820713 | 1.00 | MGAM (0.34) | MGAMGAASIMGAM2GPR3 | |
| SCHEMBL8217698 | 0.88 | VCP (0.41) | MGAMNPFFR1NPFFR2 | |
| SCHEMBL3929971 | 0.88 | VCP (0.41) | MGAMNPFFR1NPFFR2 | |
| SCHEMBL17841378 | 0.86 | NFE2L2 (0.40) | GAAGPR3 | |
| SCHEMBL17841380 | 0.86 | NFE2L2 (0.40) | GAAGPR3 | |
| SCHEMBL17841377 | 0.86 | NFE2L2 (0.40) | GAAGPR3 | |
| SCHEMBL17841381 | 0.86 | NFE2L2 (0.40) | GAAGPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2022198196-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | MGAM 267/4885GAA 28/4885SI 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.